Service d'Ophtalmologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Université Paris-Saclay, Centre de Référence Maladies Rares en Ophtalmologie (OPHTARA), 78, rue du Général Leclerc, 94275, Le Kremlin Bicêtre, France.
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France.
Orphanet J Rare Dis. 2021 Jan 30;16(1):55. doi: 10.1186/s13023-021-01707-6.
Thygeson's superficial punctate keratitis (TSPK) is a rare and still poorly understood disease of the ocular surface, responsible for recurrent episodes of photophobia and eye pain. While TSPK is considered as a benign condition, a subset of patients has frequent recurrences or even chronic disease, two situations in which there are currently no therapeutic guidelines. We used a preexisting Facebook TSPK patient support group to assess the clinical journey and the burden of disease of TSPK.
An online survey was sent to the patient support group. The first part of the questionnaire gathered information on demographics and the patient's clinical journey [diagnostic modalities, symptoms, duration and frequency of recurrent episodes (RE), efficacy and tolerance to treatments]. The second part focused on quality of life (QoL) using the Ocular Surface Disease-QoL (OSD-QoL) questionnaire. Seventy-two patients out of 595 members of the support group completed the questionnaire during the 3-months study period. Eighty percent of patients developed symptoms before 30 years old, and 47% reported a delay in the diagnosis above 1 year. Sixty percent of patients reported over 5 RE yearly, and 18% of RE lasted more than 3 months. Forty percent of all patients used cyclosporine eyedrops (50% of those with > 5 episodes/year) and it was perceived as effective by 72% of these patients. The impact on daily life activities was judged as severe by 22% of patients, while 38% reported reduced professional activity and 80% were deeply saddened by their eye condition.
TSPK patients may present with frequent recurrences and/or chronic disease, that result in a severe impact on QoL, and an off-label use of topical immunomodulatory eye drops, suggesting the urgent need for controlled studies. The utility of using social networks for rare ophthalmic disease research includes, faster data collection, data from patients across the globe, and also raises relevant questions about their real needs.
泰格松氏浅层点状角膜炎(TSPK)是一种罕见且仍未被充分了解的眼表疾病,可导致反复发作的畏光和眼部疼痛。虽然 TSPK 被认为是一种良性疾病,但有一部分患者会出现频繁复发甚至慢性疾病,目前针对这两种情况尚无治疗指南。我们利用现有的 Facebook TSPK 患者支持小组来评估 TSPK 的临床病程和疾病负担。
我们向患者支持小组发送了在线调查。问卷的第一部分收集了人口统计学信息和患者的临床病程[诊断方式、症状、复发次数和频率(RE)、治疗效果和耐受性]。第二部分使用眼表疾病生活质量(OSD-QoL)问卷重点关注生活质量(QoL)。在为期 3 个月的研究期间,支持小组的 595 名成员中有 72 名完成了问卷。80%的患者在 30 岁之前出现症状,47%的患者诊断延误超过 1 年。60%的患者每年发生超过 5 次 RE,18%的 RE 持续时间超过 3 个月。所有患者中有 40%使用环孢素滴眼剂(每年超过 5 次 RE 的患者中有 50%使用),其中 72%的患者认为该药有效。22%的患者认为对日常生活活动的影响严重,而 38%的患者报告说职业活动减少,80%的患者对自己的眼部状况深感难过。
TSPK 患者可能会出现频繁复发和/或慢性疾病,导致生活质量受到严重影响,并出现眼局部免疫调节滴眼剂的标签外使用,这表明迫切需要进行对照研究。利用社交网络进行罕见眼科疾病研究的优点包括:更快的数据收集、来自全球各地患者的数据,同时也提出了关于他们真实需求的相关问题。